Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Programmed Cell Death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies called checkpoint ...

NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced an ...

This valuable study provides solid support for the participation of the BMP-binding domain of MuSK, a tyrosine kinase mostly known for its role at the neuromuscular junction, in the maintenance and ...

Ovarian cancer presents significant challenges due to its tumor microenvironment—a complex network of cells, molecules, and ...

The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.

Patients with Huntington’s disease have a genetic mutation that triggers proteins to misfold and clump together in the brain.

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...